The present invention relates to various compositions and methods of using these compositions for imaging natriuretic peptide receptors using, for example, positron emission tomography.

The present invention provides a method for the generation of .sup.223Ra of pharmaceutically tolerable purity comprising i) preparing a generator mixture comprising .sup.227Ac, .sup.227Th and .sup.223Ra; ii) loading said generator mixture onto a strong base anion exchange resin; iii) eluting said .sup.223Ra from said strong base anion exchange resin using a first mineral acid in an alcoholic aqueous solution to give a first eluted .sup.223Ra solution; iv) loading the .sup.223Ra of the first eluted .sup.223Ra solution onto a strong acid cation exchange resin; and v) eluting the .sup.223Ra from said strong acid cation exchange resin using a second mineral acid in aqueous solution to provide a second eluted solution. The invention additionally provides products of corresponding purity and/or products obtained or obtainable by such a method.

The present invention encompasses compositions comprising two spectrally distinct radionuclides separated by a site susceptible to cleavage. Compositions of the invention may be used to detect enzyme activity and/or image diseases associated with said enzyme activity.

The present invention relates to radionuclide complex solutions of high concentration and of high chemical stability, that allows their use as drug product for diagnostic and/or therapeutic purposes. The stability of the drug product is achieved by at least one stabilizer against radiolytic degradation. The use of two stabilizers introduced during the manufacturing process at different stages was found to be of particular advantage.

Provided herein are phospholipid-free small unilamellar vesicle (PFSUV) compositions, including a steroid and a non-ionic surfactant wherein the molar ratio of steroid:nonionic surfactant is between 3:1 to 5:1. Furthermore, the compositions described herein were found to useful for drug loading, drug delivery where preferential targeting of drugs to the liver is of interest.

A method of treating a patient with a tumor, and kits (200) for such treatment. The method includes administering, to the patient, a substance (204) which activates cytoplasmatic sensors for intracellular pathogen in the tumor and treating the tumor with intra-tumoral alpha-emitter radiotherapy within two weeks of administering the substance which activates cytoplasmatic sensors for intracellular pathogen in the tumor.

The invention provides a method of preparing a .sup.89Zr-oxine complex of the formula ##STR00001##
The invention also provides a method of labeling a cell with the .sup.89Zr-oxine complex and a method for detecting a biological cell in a subject comprising administering the .sup.89Zr-oxine complex to the subject.

Disclosed herein are kits and methods for preparing radiopharmaceuticals. The kits and methods of the present disclosure can prepare the radiopharmaceuticals without using a heater and computer monitoring equipment. The kit includes a frozen crystal reaction vial, a reagent vial and a labeling holder, wherein the labeling holder contains a heating bag that can heat up to a high temperature of at least 95° C. by adding an aqueous solution.

The present disclosure provides a method for lifting submucosal or mucosal tissues in a patient, comprising administrating to the tissues an effective amount of a thermosensitive gel composition comprising Poloxamer-407. A method for performing an endoscopic procedure, a method for submucosal or mucosal resectioning, a method for performing an endoscopic ultrasound procedure, and a method for performing a polyp removal are also provided.

This disclosure relates generally to compositions and methods for treating cancer. The compositions comprise bacterially derived intact minicells or intact killed bacterial cells.